<DOC>
	<DOCNO>NCT01269476</DOCNO>
	<brief_summary>This randomise , double-blind , group-sequential , placebo-controlled , safety pharmacokinetic study healthy , aged volunteer . Objectives : 1. confirm previously report safety profile oral SNX-001 single multiple dose 3.6 , 7.2 10.8 mg compare placebo 2. establish SNX-001 pharmacokinetic profile .</brief_summary>
	<brief_title>Safety Pharmacokinetics SNX-001 Healthy Aged Volunteers</brief_title>
	<detailed_description>This study exploratory study design group sequential single multiple escalate dose , double-blind within cohort , randomize , placebo control study investigate safety tolerability well pharmacokinetics pharmacodynamics SNX-001 give oral dos age volunteer .</detailed_description>
	<mesh_term>Methanesulfonyl fluoride</mesh_term>
	<criteria>Healthy male female Physically mentally healthy subject Body weight &gt; 60 kg body weight â‰¤ 100 kg Evidence clinically significant hepatic , renal , gastrointestinal , cardiovascular , pulmonary , haematological , psychiatric , neurological significant acute chronic abnormality History general malignant diseases Evidence myasthenic weakness Acute infection febrile illness</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>